Financial Times FT.com

Actelion could strike almorexant deal soon; GSK and Novartis remain

By Andre Sawyer in London and Sasha Damouni in New York

Published: May 9 2008 17:04 | Last updated: May 9 2008 17:04

Email options

The information entered on this page will not be used to send unsolicited email, and will not be sold to a 3rd party.Terms of use |Privacy policy

* required fields



(Separate multiple e-mail addresses with commas. Limited to 20 addresses.)